Cures, jobs, ethics on the line in vote on stem cell research
By Megha Satyanarayana,
Detroit Free Press
| 09. 24. 2008
Opposing sides dig in as vote nears on Proposal 2
Ryan Dinkgrave lived a carefree life in Livonia until he was diagnosed with type I diabetes at age 10. Suddenly everything was ordered and careful.
"It makes you rethink everything you do," he said. "You're young, you're told you need to do shots, you're measuring your blood sugar. You have to count, carefully measure everything you eat."
Dinkgrave, now 25 and of Royal Oak, is among Michigan residents who support Proposal 2, a November ballot initiative allowing Michigan researchers to make embryonic stem cell cultures from excess embryos donated from fertility treatments. Researchers say the cells could unlock the secrets of disease and lead to cures for illnesses such as Alzheimer's and type I diabetes.
Voters will decide this emotionally charged issue on the basis of a 100-word ballot initiative -- one that could not only affect people's health, but also the economy of Michigan for decades to come. Proponents say the measure could spark a life sciences sector and pump billions of dollars into the state's struggling economy.
Opponents insist embryonic stem cell research is unnecessary because alternative types...
Related Articles
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...